Royalty Pharma PLC

Common Name

Royalty Pharma

Country

United States

Sector

Healthcare

Industry

Biotechnology

Employees

N/A

Ticker

RPRX

Exchange

NASDAQ/NGS

Website

www.royaltypharma.com

Description

Royalty Pharma plc is a unique player in the pharmaceutical sector, specializing in the acquisition of biopharmaceutical royalties. Its primary function is to provide critical funding to research and ... Show more

Financial Statements of Royalty Pharma

Below are the financial statements of Royalty Pharma, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.

Income Statement (as reported) Balance Sheet (as reported)

All figures in millions of USD	2024	2023	2022
Income and other revenues	—	—	—
Income from financial royalty assets	2,149.42^a	2,197.75^a	2,125.1^a
Other royalty income and revenues	114.15^a	156.8^a	112.12^a
Total income and other revenues	2,263.58^a	2,354.55^a	2,237.22^a
Operating expense	—	—	—
Provision for changes in expected cash flows from financial royalty assets	-732.46^a	-560.66^a	-904.24^a
Research and development funding expense	-2^a	-52^a	-177.11^a
Amortization of intangible assets	0^a	0^a	-5.67^a
General and administrative expenses	-236.67^a	-249.75^a	-227.3^a
Financial royalty asset impairment	0^a	0^a	-615.83^a
Total operating expense, net	-971.13^a	-862.4^a	-1,930.15^a
Operating income	1,292.44^a	1,492.15^a	307.07^a
Other (income)/expense	—	—	—
Equity in (earnings)/losses of equity method investees	-29.61^a	-28.88^a	8.97^a
Interest expense	-225.51^a	-187.19^a	-187.96^a
Losses/(gains) on derivative financial instruments	6^a	2.29^a	-96.61^a
(Gains)/losses on equity securities	-39.55^a	-87.14^a	33.44^a
(Gains)/losses on available for sale debt securities	-154.91^a	-230.84^a	6.82^a
Interest income	-47.34^a	-72.29^a	-78.34^a
Other non-operating expenses, net	1.53^a	21.74^a	14.76^a
Total other (income)/expense, net	-38.37^a	-207.94^a	77^a
Consolidated net income before tax	1,330.81^a	1,700.09^a	230.06^a
Income tax expense	0^a	0^a	0^a
Consolidated net income	1,330.81^a	1,700.09^a	230.06^a
Net income attributable to non-controlling interests	471.83^a	565.25^a	187.23^a
Net income attributable to Royalty Pharma plc	858.98^a	1,134.83^a	42.83^a

Verified Sources Behind Royalty Pharma’s Financial Fundamentals Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Royalty Pharma’s data sources below and access millions more through our Disclosure Search.

a. Royalty Pharma's 10-K 2024

Trace every data point back to Royalty Pharma’s disclosures

Sign up for Tracenable and access millions of corporate disclosures, including annual reports and sustainability filings from global companies, completely free of charge.

Real-Time & Standardized Financials

Access Standardized Financial Statements within Minutes of Disclosure

At Tracenable, we're exploring the launch of real-time standardized financial datafeeds and APIs covering global equities. Unlike limited and inconsistent XBRL parsing, our approach aims to deliver clean, comparable, and fully traceable data seconds after publication.

Could this solution support your investment or analytical workflows?

Explore Peer Companies

Welcome Back to Tracenable

Sign in to your account

Royalty Pharma PLC

Financial Statements of Royalty Pharma

Verified Sources Behind Royalty Pharma’s Financial Fundamentals Data

Access Standardized Financial Statements within Minutes of Disclosure

Explore Peer Companies

Halozyme Therapeutics Inc

Bio-Techne Corp

Incyte Corp

Immunovant Inc

Ultragenyx Pharmaceutical Inc

Cytokinetics Inc